Physician profile
Allyson M Fields
NPI 1235525098
$13,060.22
in general payments reported to CMS, 2019-2025
30 companies · $3,302 in 2025
The $3,302 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,785 · 2022: $1,255 · 2023: $3,230 · 2024: $3,487 · 2025: $3,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,558 · Education: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,557.82 |
| Education | $462.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,278.45 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,099.92 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $1,071.12 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $988.18 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Galderma Laboratories, L.P. | $957.65 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Regeneron Healthcare Solutions, INC. | $879.45 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $845.67 | 2021-2025 | |
| Amgen INC. | $625.35 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $548.25 | 2021-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $488.44 | 2022-2025 | |
| Pfizer INC. | $485.95 | 2021-2025 | |
| Organon LLC | $281.39 | 2024-2025 | Vtama |
| Incyte Corporation | $278.95 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $275.14 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $267.89 | 2022-2025 | Taltz, Ebglyss, Olumiant |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $245.43 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $225.51 | 2023-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $208.94 | 2023-2025 | |
| Genzyme Corporation | $208.88 | 2021-2025 | |
| Verrica Pharmaceuticals INC. | $190.82 | 2024-2025 | Ycanth |
| Biofrontera INC. | $139.04 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 | |
| Vyne Pharmaceuticals INC. | $121.01 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.04 | 2023-2025 | Jublia, Arazlo, Cabtreo |
| Dermira, INC. | $40.10 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.21 | 2025 | Spevigo |
| Kyowa Kirin, INC. | $17.69 | 2022 | |
| Sebela Pharmaceuticals INC. | $16.37 | 2022 | |
| Epi Health, LLC | $14.39 | 2021 | |
| Almirall LLC | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.